Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals
Jian Zhang,Qian Wu,Ziyan Liu,Qijie Wang,Jiajing Wu,Yabin Hu,Tingting Bai,Ting Xie,Mincheng Huang,Tiantian Wu,Danhong Peng,Weijin Huang,Kun Jin,Ling Niu,Wangyuan Guo,Dixian Luo,Dongzhu Lei,Zhijian Wu,Guicheng Li,Renbin Huang,Yingbiao Lin,Xiangping Xie,Shuangyan He,Yunfan Deng,Jianghua Liu,Weilang Li,Zhongyi Lu,Haifu Chen,Ting Zeng,Qingting Luo,Yi-Ping Li,Youchun Wang,Wenpei Liu,Xiaowang Qu
DOI: https://doi.org/10.1038/s41564-020-00824-5
IF: 28.3
2020-11-16
Nature Microbiology
Abstract:Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)<sup><a href="#ref-CR1">1</a>,<a href="#ref-CR2">2</a>,<a href="/articles/s41564-020-00824-5#ref-CR3">3</a></sup> and individuals with COVID-19 have symptoms that can be asymptomatic, mild, moderate or severe<sup><a href="/articles/s41564-020-00824-5#ref-CR4">4</a>,<a href="/articles/s41564-020-00824-5#ref-CR5">5</a></sup>. In the early phase of infection, T- and B-cell counts are substantially decreased<sup><a href="/articles/s41564-020-00824-5#ref-CR6">6</a>,<a href="/articles/s41564-020-00824-5#ref-CR7">7</a></sup>; however, IgM<sup><a href="#ref-CR8">8</a>,<a href="#ref-CR9">9</a>,<a href="#ref-CR10">10</a>,<a href="/articles/s41564-020-00824-5#ref-CR11">11</a></sup> and IgG<sup><a href="#ref-CR12">12</a>,<a href="#ref-CR13">13</a>,<a href="/articles/s41564-020-00824-5#ref-CR14">14</a></sup> are detectable within 14 d after symptom onset. In COVID-19-convalescent individuals, spike-specific neutralizing antibodies are variable<sup><a href="/articles/s41564-020-00824-5#ref-CR3">3</a>,<a href="/articles/s41564-020-00824-5#ref-CR15">15</a>,<a href="/articles/s41564-020-00824-5#ref-CR16">16</a></sup>. No specific drug or vaccine is available for COVID-19 at the time of writing; however, patients benefit from treatment with serum from COVID-19-convalescent individuals<sup><a href="/articles/s41564-020-00824-5#ref-CR17">17</a>,<a href="/articles/s41564-020-00824-5#ref-CR18">18</a></sup>. Nevertheless, antibody responses and cross-reactivity with other coronaviruses in COVID-19-convalescent individuals are largely unknown. Here, we show that the majority of COVID-19-convalescent individuals maintained SARS-CoV-2 spike S1- and S2-specific antibodies with neutralizing activity against the SARS-CoV-2 pseudotyped virus, and that some of the antibodies cross-neutralized SARS-CoV, Middle East respiratory syndrome coronavirus or both pseudotyped viruses. Convalescent individuals who experienced severe COVID-19 showed higher neutralizing antibody titres, a faster increase in lymphocyte counts and a higher frequency of CXCR3<sup>+</sup> T follicular help (T<sub>FH</sub>) cells compared with COVID-19-convalescent individuals who experienced non-severe disease. Circulating T<sub>FH</sub> cells were spike specific and functional, and the frequencies of CXCR3<sup>+</sup> T<sub>FH</sub> cells were positively associated with neutralizing antibody titres in COVID-19-convalescent individuals. No individuals had detectable autoantibodies. These findings provide insights into neutralizing antibody responses in COVID-19-convalescent individuals and facilitate the treatment and vaccine development for SARS-CoV-2 infection.
microbiology